HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autologous bone marrow transplantation in secondary acute monoblastic leukemia following Hodgkin's disease.

Abstract
Acute non lymphocytic leukemia (AnLL) is the most common second malignancy (SM) in survivors of childhood Hodgkin's Disease (HD). Chemotherapy responsiveness is usually poor and death ensues briefly after diagnosis. We report the case of a 13 year-old girl, affected by HD, stage IV, mixed cellularity, who developed AnLL one year after the HD treatment was stopped. Autologous Bone Marrow Transplantation (ABMT) was performed 9 months after complete remission (CR) was achieved by chemotherapy. Presently, the patient is alive and on continues CR, 3 years and 7 months after ABMT. ABMT may be a promising approach for secondary AnLL, the prognosis of which is almost invariably fatal with conventional chemotherapy.
AuthorsF Rossetti, C Messina, P Colleselli, G De Silvestro, G Sotti, R Destro, L Zanesco
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 7 Suppl 3 Pg. 131-2 ( 1991) ISSN: 0268-3369 [Print] England
PMID1855076 (Publication Type: Case Reports, Journal Article)
Topics
  • Adolescent
  • Bone Marrow Transplantation (methods)
  • Female
  • Hodgkin Disease (complications, pathology)
  • Humans
  • Leukemia, Monocytic, Acute (etiology, pathology, surgery)
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: